Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 15, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain financial performance data for a specific fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share ownership changes and contains no financial statements or operational metrics.
Material Changes
The filing details specific changes in shareholdings for directors and the GlaxoSmithKline Employee Trust (GSK Trust):
- Mr. J D Coombe: Increased his interest by 109 Ordinary Shares on January 13, 2004, at a price of £12.17 per share, resulting from the re-investment of dividends paid on January 6, 2004.
- GSK Trust Transfers:
- On January 12, 2004, the Trust transferred 11,589 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- On January 13, 2004, the Trust transferred 9,164 Ordinary Shares to participants in the same plan.
- Director Interests in Trust: Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe hold interests in the shares held by the GSK Trust as potential beneficiaries, consistent with other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting statutory changes in director shareholdings.
Key Facts for Investor Verification
- Verify the impact of the dividend reinvestment on Mr. Coombe's total holdings.
- Confirm the total number of shares transferred from the GSK Trust to the Employee Share Option Plan during the reporting week (20,753 shares total).
- Note that the share price referenced for the dividend reinvestment was £12.17.
- Understand that this filing does not reflect operational performance or financial health.